Back
ESC Premium Access

Benefit of LDL-C lowering with evolocumab on cardiovascular outcomes by age & sex: an analysis of the FOURIER trial

Session: PCSK9 inhibitors - For the many or the few?
Topic: Lipid-Lowering Agents
Speaker: Professor P. Sever (London, GB)
Event: ESC Congress 2018

Congress Presentation

0

About the speaker

Professor Peter S Sever

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)
4 presentations
1 follower

4 more presentations in this session

PCSK9 Inhibitors - State of the art

Speaker: Professor J. Armitage (Oxford, GB)

Access
Slides
Video
0
Thumbnail

PCSK9-Inhibitor treatment of cardiovascular high risk patients in a real-world setting

Speaker: Doctor U. Kassner (Berlin, DE)

Access
Abstract
Slides
Video
0
Thumbnail

Inhibition of PCSK9 reduces infarct size and arrhythmia susceptibility in cardiac ischeamia/reperfusion injury through attenuating mitochondrial dysfunction and increasing connexin43 phosphorylation

Speaker: Doctor S. Palee (Chiang Mai, TH)

Access
Abstract
Slides
Video
0
Thumbnail

Future hurdles in PCSK9 - Inhibition.

Speaker: Professor E. Stein (Cincinnati, US)

Access
Slides
Video
0
Thumbnail

Access the full session

PCSK9 inhibitors - For the many or the few?

Speakers: Professor P. Sever, Professor J. Armitage, Doctor U. Kassner, Doctor S. Palee, Professor E. Stein
Access
0
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk